Remission at 6 months was recorded in 73.1% of rituximab-treated patients and 40.1% of cyclophosphamide-treated patients in a multicenter target trial emulation.
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the
Feb 19, 2021
THURSDAY, Feb. 18, 2021 (HealthDay News) Avacopan is noninferior, but not superior, to prednisone with respect to remission at week 26 for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, according to a study published in the Feb. 18 issue of the
New England Journal of Medicine.
David R.W. Jayne, M.D., from Addenbrooke’s Hospital in Cambridge, United Kingdom, and colleagues randomly assigned 331 patients with ANCA-associated vasculitis to receive either oral avacopan or oral prednisone on a tapering schedule (166 and 165 patients, respectively). All patients received standard therapy for remission induction with either cyclophosphamide (followed by azathioprine) or rituximab.
The researchers found that in both groups, the mean Birmingham Vasculitis Activity Score (BVAS) at baseline was 16; the first primary end point (remission, defined as a BVAS of 0) was observed in 72.3 and 70.1 percent receiving avacopan and prednisone, respect